Drug Profile
Research programme: diabetes therapeutics - Sprint Bioscience
Alternative Names: STK25 - Sprint BioscienceLatest Information Update: 28 Dec 2019
Price :
$50
*
At a glance
- Originator Sprint Bioscience
- Developer Goteborg University; Sprint Bioscience
- Class Antihyperglycaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 28 Dec 2019 No recent reports of development identified for research development in Type-2-diabetes-mellitus in Sweden
- 30 Nov 2015 Sprint Bioscience and Gothenburg University collaborate to develop new drug candidates for the treatment of type-2 diabetes
- 30 Nov 2015 Early research in Type-2 diabetes mellitus in Sweden (unspecified route)